Press coverage about Zai Lab (NASDAQ:ZLAB) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zai Lab earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.5470225594896 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Zai Lab (NASDAQ:ZLAB) traded down 0.11% on Friday, reaching $27.00. The company’s stock had a trading volume of 374,039 shares. Zai Lab has a 12-month low of $23.80 and a 12-month high of $32.64. The company’s market capitalization is $1.33 billion.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Zai Lab (ZLAB) Stock Price” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Receive News & Ratings for Zai Lab Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.